Navigation Links
Experimental TB drug explodes bacteria from the inside out
Date:11/27/2008

An international team of biochemists has discovered how an experimental drug unleashes its destructive force inside the bacteria that cause tuberculosis (TB). The finding could help scientists develop ways to treat dormant TB infections, and suggests a strategy for drug development against other bacteria as well.

A report describing the research, led by Clifton E. Barry, III, Ph.D., of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is published in the Nov. 28 issue of Science. Dr. Barry's collaborators included scientists from NIAID and from the Novartis Institute for Tropical Diseases in Singapore.

One-third of the world's population is infected with Mycobacterium tuberculosis (M. tb), the bacteria that cause TB. "Currently, there are no drugs available that specifically target latent tuberculosis infections in which bacteria are present but are not actively dividing," notes NIAID Director Anthony S. Fauci, M.D. "Dr. Barry and his colleagues have now given us a detailed picture of how the candidate TB drug PA-824 is metabolized inside Mycobacterium tuberculosis. Their discovery is a promising step towards developing effective drugs against latent TB as well as other bacteria."

Previously, Dr. Barry and his collaborators found that M. tb mutants lacking a specific bacterial enzyme were resistant to PA-824, but at that time, they did not know the function of the enzyme.

"It took several years, but at last we were able to recreate in the test tube what happens inside mycobacterial cells when the bacterial enzyme, which we named Ddn, and a second bacterial component called a cofactor, interact with PA-824," says Dr. Barry. The key event in PA-824 metabolism, they found, is the production of nitric oxide (NO) gas. "This highly reactive molecule," he adds, "is akin to a bomb blast that kills the bacteria from within."

NO gas is produced naturally by
'/>"/>

Contact: Anne A. Oplinger
aoplinger@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Cephalon and ImmuPharma Sign a $15 million Option Agreement for Late- Stage Experimental Lupus Medication
2. Phase II Trial of Experimental Anti-Coagulant Reports Safety and Outcomes Data
3. Experimental Apartment in Beijing Achieves 99% Purity of Indoor Air
4. Experimental Drug Fights Multiple Sclerosis Activity
5. Experimental Therapy Beats Back One Patients Melanoma
6. Experimental agent blocks prostate cancer in animal study
7. Experimental Drug Eases Symptoms of Mild Alzheimers
8. Experimental Blood Substitutes Unsafe, Study Finds
9. Honda to Showcase Experimental Walking Assist Device
10. Experimental Alzheimers Drug Shows Promise
11. Experimental drug shows promise in treating certain lymphomas
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Americans United for Life Condemns Ruling Increasing Minors' Access to Dangerous Plan B 2Health News:AANS President to Testify on Patient Access to Care 2Health News:Transcept Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results 2Health News:Transcept Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results 3Health News:Transcept Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results 4Health News:Transcept Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results 5Health News:Transcept Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results 6Health News:Transcept Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results 7Health News:Transcept Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results 8Health News:Transcept Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results 9Health News:Transcept Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results 10Health News:Transcept Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results 11Health News:Transcept Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results 12Health News:Young Survival Coalition and Living Beyond Breast Cancer Announce Support for Rep. Wasserman Schultz's 'The Early Act' 2Health News:Lowest Blood Pressure, Cholesterol Levels the Best 2Health News:Lowest Blood Pressure, Cholesterol Levels the Best 3
Breaking Medicine Technology:Lentigen Awarded Phase I SBIR Grant for Hepatitis C Vaccine 2Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 2Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 3Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 4Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 5Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 2Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 3Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 4Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 5Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 6Valeant Grants Schering Plough Exclusive Option in Japan for Taribavirin in Exchange for Release of Last Right of Refusal 47437 1Valeant Grants Schering Plough Exclusive Option in Japan for Taribavirin in Exchange for Release of Last Right of Refusal 47437 2Valeant Grants Schering Plough Exclusive Option in Japan for Taribavirin in Exchange for Release of Last Right of Refusal 47437 3Rigels R788 Evaluated in Phase 2 Trial in Multiple Cancers 47432 1Rigels R788 Evaluated in Phase 2 Trial in Multiple Cancers 47432 2Rigels R788 Evaluated in Phase 2 Trial in Multiple Cancers 47432 3SAFC Pharmas St Louis HPAPI Conjugates Facility Receives SafeBridge Certification 47429 1SAFC Pharmas St Louis HPAPI Conjugates Facility Receives SafeBridge Certification 47429 2SAFC Pharmas St Louis HPAPI Conjugates Facility Receives SafeBridge Certification 47429 3